Navigation Links
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
Date:7/28/2011

p three percent versus the comparable quarter last year, our North American business grew at a seven percent clip.  For the quarter, our international business was down 12 percent, primarily attributable to timing issues in the booking of certain orders through distributors.  We expect the bulk of those orders to be recognized in the near future.  We sold a total of 1.6 million reagent disc units across all product lines during the quarter; which is the third highest quarter in reagent disc unit sales in the history of the company."

Mr. Severson continued, "As we have previously disclosed, legal expenses associated with the on-going intellectual property infringement case impacted the results of the quarter.  As a company founded on innovation, and one that continues to be a leader in new technologies, we believe that infringement of our intellectual property is something we must take very seriously.  We are pleased that the financial underpinnings of the company remain very strong as evidenced by solid profitability for the quarter and an increase in our cash, cash equivalents and investments of $10.5 million to $108.9 million compared to the same period last year.  As we move forward, we expect that fiscal year 2012 will continue the trajectory of growth set in recent years."

Conference CallAbaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Thursday, July 28, 2011.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call will be available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, access code 10002131, through August 3, 2011.  This
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
2. Abaxis to Present at Jefferies 2011 Global Healthcare Conference
3. Abaxis to Present at ThinkEquitys Second Annual Healthcare Conference
4. Abaxis Receives Presidential "E" Award for Exports
5. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
6. Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Abaxis Appoints Vernon Altman to Board of Directors
8. Abaxis to Report Fourth Quarter and Fiscal Year 2011 Financial Results Thursday, April 28, 2011
9. Abaxis, Inc. to Present at the 10th Annual Needham Healthcare Conference
10. Abaxis, Inc. to Present at RBC Capital Markets Healthcare Conference
11. Abaxis Reports Financial Performance With Record Sales for the Third Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the developer ... metabolic diseases and other gastrointestinal disorders, today announced that ... the Board of Directors, effective July 31, 2015.  Ms. ... the 2018 annual meeting or until her successor is ... in an executive capacity in the healthcare industry for ...
(Date:8/2/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... discover and develop antisense therapies for cardiovascular, metabolic ... a broad existing relationship between the two companies ... areas using novel RNA-targeted treatments. It also enables ... technology to diseases of the kidney. ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4
... statins for only five weeks at,400 mg/week lowered ... with similarly favorable effects on other,atherogenic lipids, NEW ... Isis Pharmaceuticals, Inc. announced new,results from its Phase ... presented today at the of Cardiology,Annual Scientific Session ...
... Only Illinois Site in Trial , CHICAGO, March ... adult stem cell therapy, Provacel™,experienced a lower number ... significant improvements in heart, lung and,global function compared ... Phase I study data presented at the American ...
Cached Medicine Technology:Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 2Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 3
(Date:8/3/2015)... , ... August 03, 2015 , ... ... agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions ... health care costs. , Annually, more than 8.6 million adverse drug events ...
(Date:8/3/2015)... FL (PRWEB) , ... August ... ... most-visited bodybuilding and fitness site and the largest online retailer of nutritional ... Awards. BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. ... lifecycle management solution, as well as announced the date of its next major ... ease of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical ... on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New ... may be accessed via the investor relations section of the Company’s website. , About ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration ... is similar to deoxycholic acid, which occurs naturally in the body and helps absorb ... treat this area of the body. These are invasive procedures and very expensive for ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Exposure to environmental levels of the industrial chemical bisphenol A, ... long-lasting harm to testicular function, according to a new study ... The Endocrine Society,s 92nd Annual Meeting in San Diego. ... after exposure to BPA levels that are lower than what ...
... revelation that the chair of the board of Canada,s ... until April 2010 sends an unfortunate message to the ... states an editorial http://www.cmaj.ca/cgi/doi/10.1503/cmaj.100850 in CMAJ ( ... no place for the tobacco industry on the development ...
... , ... rank search results higher when there is promoter activity behind the website. , ... (PRWEB) June 21, 2010 -- The Active ... called Active Search Results Page Ranking Technology (ASR Ranking). , , ,ASR Ranking allows ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... performance for the year ending March 31, 2010 in spite of the economic turmoil’s impact ... the second half of 2010 compared with the same period last year. , ... Auckland, New Zealand (Vocus) June 21, 2010 ...
... The ... 33 times greater than that reported for our accredited ambulatory surgery centers. , ... (PRWEB) June 18, 2010 ... Michael Jhung et al (JAMA 2010;303(22):2273 - 2279) correctly places emphasis on the importance ...
Cached Medicine News:Health News:Early-life exposure to BPA may affect testis function in adulthood 2Health News:CMAJ calls for resignation of IDRC chair Barbara McDougall 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 3Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 4Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 5Health News:Infection Rate in Accredited Ambulatory Facilities is Lower than in Hospitals 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: